MX355408B - Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. - Google Patents

Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.

Info

Publication number
MX355408B
MX355408B MX2014015643A MX2014015643A MX355408B MX 355408 B MX355408 B MX 355408B MX 2014015643 A MX2014015643 A MX 2014015643A MX 2014015643 A MX2014015643 A MX 2014015643A MX 355408 B MX355408 B MX 355408B
Authority
MX
Mexico
Prior art keywords
oligonucleotides
chemically modified
oligonucleotide
locked nucleic
nucleic acid
Prior art date
Application number
MX2014015643A
Other languages
English (en)
Other versions
MX2014015643A (es
Inventor
Van Rooij Eva
M Dalby Christina
L Montgomery Rusty
Original Assignee
Miragen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miragen Therapeutics Inc filed Critical Miragen Therapeutics Inc
Publication of MX2014015643A publication Critical patent/MX2014015643A/es
Publication of MX355408B publication Critical patent/MX355408B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Abstract

La presente invención se refiere a de modificación química para oliqonucleótidos. Los oligonucleótidos de la presente invención, tales como los oligonucleótidos anti-sentido modificados químicamente, pueden tener eficacia aumentada in vivo. Los oligonucleótidos modificados químicamente proporcionan ventajas en uno o más de potencia, eficacia de suministro, especificidad, toxicidad y/o estabilidad blanco. Los oliqonucleótidos modificados químicamente tienen un motivo o patrón de modificación química específica de ácidos nucleicos bloqueados (LNA). El oligonucleótido (por ejemplo el oligonucleótido anti-sentido) puede dirigirse a un ARN, tal como miARN o mARN. También se proporcionan en la presente composiciones que comprenden los oligonucleótidos modificados químicamente y los métodos para utilizar los oligonucleótidos modificados químicamente como terapéuticos para diversos trastornos, entre los que se incluyen trastornos cardiovasculares.
MX2014015643A 2012-06-21 2013-06-21 Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. MX355408B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662746P 2012-06-21 2012-06-21
US201361801533P 2013-03-15 2013-03-15
PCT/US2013/047157 WO2013192576A2 (en) 2012-06-21 2013-06-21 Oligonucleotide-based inhibitors comprising locked nucleic acid motif

Publications (2)

Publication Number Publication Date
MX2014015643A MX2014015643A (es) 2015-07-17
MX355408B true MX355408B (es) 2018-04-18

Family

ID=49769732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015643A MX355408B (es) 2012-06-21 2013-06-21 Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.

Country Status (12)

Country Link
US (3) US9388408B2 (es)
EP (2) EP3354734B1 (es)
JP (2) JP6208228B2 (es)
KR (1) KR101928418B1 (es)
CN (2) CN107236735B (es)
AU (1) AU2013278011B2 (es)
CA (1) CA2876180C (es)
DK (1) DK3354734T3 (es)
ES (1) ES2801875T3 (es)
HK (2) HK1209781A1 (es)
MX (1) MX355408B (es)
WO (1) WO2013192576A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504857A (ja) * 2010-12-15 2014-02-27 ミラゲン セラピューティクス ロックドヌクレオチドを含むｍｉｃｒｏＲＮＡ阻害剤
HUE054129T2 (hu) 2011-04-25 2021-08-30 Sanofi Sa Mikro-RNS vegyületek és eljárások miR-21 aktivitás modulálására
SG11201406931XA (en) 2012-04-25 2014-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
AU2013278011B2 (en) 2012-06-21 2018-09-20 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
EP2757157A1 (en) * 2013-01-17 2014-07-23 Ecole Polytechnique Federale de Lausanne (EPFL) Modulation of mitophagy and use thereof
EP2968396B1 (en) * 2013-03-15 2018-12-19 Miragen Therapeutics, Inc. Locked nucleic acid inhibitor of mir-145 and uses thereof
MX371093B (es) 2013-05-01 2020-01-16 Regulus Therapeutics Inc Compuestos de microarn y metodos para modular al mir-122.
KR20170042625A (ko) 2014-08-04 2017-04-19 미라젠 세러퓨틱스 인코포레이티드 Myh7b의 억제제 및 이의 용도
WO2016022753A1 (en) 2014-08-07 2016-02-11 Regulus Therapeutics Inc. Targeting micrornas for metabolic disorders
WO2016069717A1 (en) * 2014-10-28 2016-05-06 MiRagen Therapeutics, Inc. Inhibitors of mirnas in regulation of arterial stiffness and uses thereof
MX2017009427A (es) * 2015-01-20 2017-10-02 Miragen Therapeutics Inc Inhibidores de mir-92 y usos de los mismos.
WO2017041020A1 (en) * 2015-09-04 2017-03-09 Oregon State University Renal selective inhibition of cytochrome p450 3a5
WO2017053622A1 (en) * 2015-09-22 2017-03-30 MiRagen Therapeutics, Inc. MiR-19 MODULATORS AND USES THEREOF
EP3364984B1 (en) * 2015-10-15 2021-11-17 City of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
CA3005434A1 (en) * 2015-11-16 2017-05-26 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
CN105435247A (zh) * 2015-12-31 2016-03-30 中国医学科学院基础医学研究所 miR-378在预防和/或治疗肥胖症中的用途
WO2017187426A1 (en) * 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN106011140B (zh) * 2016-06-06 2018-12-18 同济大学 反义microRNA-25及其应用
WO2017214953A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种特异抑制人 miRNA-424 表达的慢病毒载体的构建及其应用
WO2017214952A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 特异抑制人 miRNA-185 表达的慢病毒载体的构建及其应用
WO2017219165A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异敲低人 miRNA-29a 和 miR-140 表达的慢病毒载体及其应用
WO2017219170A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用
WO2017219166A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 一种同时抑制双 miRNA 表达的慢病毒载体及其应用
US20200276220A1 (en) * 2016-07-07 2020-09-03 MiRagen Therapeutics, Inc. Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
WO2018183127A1 (en) * 2017-03-25 2018-10-04 MiRagen Therapeutics, Inc. Mir-92 inhibitors for treatment of heart failure
CN110141577A (zh) * 2018-02-13 2019-08-20 上海三炬生物科技有限公司 miRNA-24-3p核苷酸类似物在制备药物中的应用
CN111918968B (zh) * 2018-03-14 2023-11-24 贝斯以色列女执事医疗中心 Micro-RNA 22的抑制剂
WO2020051398A1 (en) * 2018-09-06 2020-03-12 Aptamir Therapeutics, Inc. Metabolic benefits of short mir-22 mirna antagomir therapies
CN110358769A (zh) * 2019-07-30 2019-10-22 中国医学科学院血液病医院(中国医学科学院血液学研究所) 经锁核酸和硫代磷酸修饰的miRNA类似物及其在制备抗肿瘤药物中的应用
CN110433170B (zh) * 2019-07-31 2021-04-27 南京医科大学 心脏抽吸液miR-28-5p在心脏疾病中的应用
WO2021097390A1 (en) * 2019-11-15 2021-05-20 Duke University Cellular molecular theranostics nanoprobe systems and methods
CN111118008B (zh) * 2020-01-16 2023-08-22 南京医科大学 Mcl1基因的3’-UTR序列及其应用
CN116438305A (zh) * 2020-07-23 2023-07-14 法兰克福大学 用于治疗心力衰竭的miRNA的组合抑制

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
AU7404994A (en) 1993-07-30 1995-02-28 Regents Of The University Of California, The Endocardial infusion catheter
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
EP1012331B1 (en) 1997-07-01 2006-03-29 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
US6833361B2 (en) 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
JP2002516256A (ja) 1998-05-26 2002-06-04 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 二環式糖成分を有する新規ヌクレオシド
IL145417A0 (en) 1999-03-18 2002-06-30 Exiqon As Detection of mutations in genes by specific lna primers
WO2001025478A1 (en) * 1999-10-04 2001-04-12 Exiqon A/S A method of increasing the specificity of oxy-lna oligonucleotides
WO2002028875A2 (en) 2000-10-04 2002-04-11 Cureon A/S Improved synthesis of purine locked nucleic acid analogues
EP2428571B1 (en) 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
US20060084617A1 (en) 2002-05-06 2006-04-20 Satishchandran C Methods for delivery of nucleic acids
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
DK2752488T3 (da) 2002-11-18 2020-04-20 Roche Innovation Ct Copenhagen As Antisense-design
ES2332178T5 (es) 2003-03-21 2014-02-04 Santaris Pharma A/S Análogos de ARN pequeños de interferencia (ARNpi)
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
EP3427585A1 (en) 2003-11-26 2019-01-16 University of Massachusetts Sequence-specific inhibition of small rna function
WO2005078139A2 (en) 2004-02-09 2005-08-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
WO2005078096A2 (en) 2004-02-09 2005-08-25 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
US7772389B2 (en) 2004-02-13 2010-08-10 Rockefeller University Anti-microRNA oligonucleotide molecules
US7722596B2 (en) 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
JP4819788B2 (ja) 2004-02-26 2011-11-24 オスプレイ メディカル インク． 分離用心循環
EP2474616B1 (en) 2004-05-28 2015-07-08 Asuragen, Inc. Methods and compositions involving microRNA
EP2281887A1 (en) 2004-11-12 2011-02-09 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2006063356A1 (en) 2004-12-10 2006-06-15 Isis Phamaceuticals, Inc. Regulation of epigenetic control of gene expression
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
WO2006069584A2 (en) 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2006089340A2 (en) 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
CN101203611B (zh) 2005-04-19 2013-08-14 巴斯福植物科学有限公司 控制基因表达的改良方法
PL2002003T3 (pl) 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
CA2903764A1 (en) 2005-12-12 2007-06-21 The University Of North Carolina At Chapel Hill Micrornas that regulate muscle cell proliferation and differentiation
EP1966390A1 (en) 2005-12-29 2008-09-10 Exiqon A/S Detection of tissue origin of cancer
EP2388328A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
CA2649045C (en) 2006-04-03 2019-06-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US8466117B2 (en) 2006-07-28 2013-06-18 The Johns Hopkins University Compositions and methods for modulating angiogenesis
JP5718570B2 (ja) 2006-08-01 2015-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ベータミオシン重鎖の発現を活性化するマイクロｒｎａの同定
WO2008042231A2 (en) 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
EP2476762B1 (de) 2006-10-09 2014-01-08 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen
WO2008147430A2 (en) 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
WO2008061537A2 (en) 2006-11-23 2008-05-29 Querdenker Aps Oligonucleotides for modulating target rna activity
WO2008076324A2 (en) 2006-12-14 2008-06-26 Novartis Ag Compositions and methods to treat muscular & cardiovascular disorders
US20090137504A1 (en) 2006-12-21 2009-05-28 Soren Morgenthaler Echwald Microrna target site blocking oligos and uses thereof
EP2113567B1 (en) 2006-12-21 2019-04-03 QIAGEN GmbH MicroRNA target site blocking oligos and uses thereof
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
WO2008131191A2 (en) 2007-04-20 2008-10-30 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
CA2687336C (en) 2007-05-23 2014-12-23 Dharmacon, Inc. Micro-rna scaffolds and non-naturally occurring micro-rnas
JP5654347B2 (ja) 2007-07-31 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ミオシンの発現及び筋線維の同一性を制御するマイクロｒｎａ
WO2009026574A2 (en) 2007-08-23 2009-02-26 Keren Pharmaceutical, Inc. Immunogenic compositions and uses thereof
EP2190992B1 (en) 2007-09-14 2013-04-03 The Ohio State University Research Foundation Mirna expression in human peripheral blood microvesicles and uses thereof
US8440637B2 (en) * 2007-10-04 2013-05-14 Santaris Pharma A/S Combination treatment for the treatment of hepatitis C virus infection
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
CN101424640B (zh) 2007-11-02 2012-07-25 江苏命码生物科技有限公司 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
EP2219653B1 (en) 2007-11-09 2016-12-21 The Board of Regents of The University of Texas System Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
JP2011512326A (ja) 2007-12-31 2011-04-21 ナノコア セラピューティクス，インコーポレイテッド 心不全の治療用のｒｎａ干渉
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
US8361980B2 (en) 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
WO2009114681A2 (en) 2008-03-13 2009-09-17 Dharmacon, Inc. Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
US20090326049A1 (en) 2008-04-04 2009-12-31 Alexander Aristarkhov Blocking oligos for inhibition of microrna and sirna activity and uses thereof
EP2297322A1 (en) 2008-06-04 2011-03-23 The Board of Regents of The University of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
WO2009151600A2 (en) 2008-06-10 2009-12-17 Tufts University Smad proteins control drosha-mediated mirna maturation
WO2010000665A1 (en) * 2008-06-30 2010-01-07 Santaris Pharma A/S Antidote oligomers
CN101386848A (zh) 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
EP3067359A1 (en) 2008-09-23 2016-09-14 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
EP2447274B1 (en) 2008-10-24 2017-10-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds and methods
US8629119B2 (en) 2009-02-04 2014-01-14 The Board Of Regents, The University Of Texas System Dual targeting of MIR-208 and MIR-499 in the treatment of cardiac disorders
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
ES2599979T3 (es) * 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
US9012225B2 (en) 2009-05-05 2015-04-21 Miragen Therapeutics Lipophilic polynucleotide conjugates
EP2440566A4 (en) * 2009-06-08 2013-10-16 Miragen Therapeutics CHEMICAL MODIFICATION RULES FOR INHIBITORS AND MIMETICS OF MIRIK
AU2010294197C9 (en) 2009-09-10 2018-09-13 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application
US9364495B2 (en) 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
US8592151B2 (en) 2009-11-17 2013-11-26 Musc Foundation For Research Development Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
US20130109738A1 (en) 2010-02-24 2013-05-02 The Board Of Trustees Of The Leland Stanford Junior University Control of Cardiac Growth, Differentiation and Hypertrophy
EP2550360B1 (en) 2010-03-24 2017-08-30 Mirrx Therapeutics A/s Bivalent antisense oligonucleotides
WO2011127625A1 (zh) 2010-04-13 2011-10-20 江苏命码生物科技有限公司 一种调节生物体内微小核糖核酸含量的方法及其用途
EP2865765B1 (en) 2010-04-20 2016-08-17 Hummingbird Diagnostics GmbH Complex miRNA sets as novel biomarkers for an acute coronary syndrome
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130150256A1 (en) 2010-06-11 2013-06-13 Jane Synnergren Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types
ITMI20101089A1 (it) 2010-06-16 2011-12-17 Istituto Naz Di Genetica Molecolare Ingm Profili di espressione di micro-rna nel sangue periferico per il monitoraggio del sistema immunitario
CA2804791C (en) 2010-07-08 2019-07-30 Duke University Direct reprogramming of cells to cardiac myocyte fate
GB201012418D0 (en) * 2010-07-23 2010-09-08 Santaris Pharma As Process
US20130137753A1 (en) 2010-08-03 2013-05-30 University Of South Alabama Methods and compositions for the diagnosis and treatment of breast cancer
WO2012020308A2 (en) 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Cellular and molecular therapies
JP6106085B2 (ja) 2010-08-24 2017-03-29 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
JP2013541334A (ja) 2010-09-15 2013-11-14 アルニラム ファーマスーティカルズ インコーポレイテッド 修飾されたｉＲＮＡ剤
CA2817002C (en) * 2010-11-05 2019-01-15 Miragen Therapeutics Base modified oligonucleotides
JP2014504857A (ja) 2010-12-15 2014-02-27 ミラゲン セラピューティクス ロックドヌクレオチドを含むｍｉｃｒｏＲＮＡ阻害剤
WO2012149646A1 (en) 2011-05-05 2012-11-08 Sunnybrook Research Institute Mirna inhibitors and their uses
EP2763703B1 (en) 2011-10-06 2018-02-14 Miragen Therapeutics, Inc. Control of whole body energy homeostasis by microrna regulation
GB201117482D0 (en) 2011-10-11 2011-11-23 Univ Dundee Targetiing of miRNA precursors
EP2584040A1 (en) 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Compounds for treatment of ischemic injury
CN107266391B (zh) 2011-10-18 2020-04-17 迪克纳制药公司 胺阳离子脂质及其用途
EP2790736B1 (en) 2011-12-12 2018-01-31 Oncoimmunin, Inc. In vivo delivery of oligonucleotides
US20140356459A1 (en) 2011-12-15 2014-12-04 Oncostamen S.R.L. Micrornas and uses thereof
EP2604690A1 (en) 2011-12-15 2013-06-19 Oncostamen S.r.l. MicroRNAs and uses thereof
FR2984358A1 (fr) 2011-12-16 2013-06-21 Genethon Methodes pour le diagnostic de dystrophies musculaires
AU2013278011B2 (en) 2012-06-21 2018-09-20 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
ES2606636T3 (es) 2013-01-24 2017-03-24 Pierre Fabre Médicament S.A.S. Composición que comprende un antagomir encapsulado
MX2017009427A (es) 2015-01-20 2017-10-02 Miragen Therapeutics Inc Inhibidores de mir-92 y usos de los mismos.

Also Published As

Publication number Publication date
KR20150023687A (ko) 2015-03-05
WO2013192576A2 (en) 2013-12-27
JP2017217007A (ja) 2017-12-14
CN104685056A (zh) 2015-06-03
US9388408B2 (en) 2016-07-12
CA2876180C (en) 2019-11-19
AU2013278011A1 (en) 2015-01-15
US20180273944A1 (en) 2018-09-27
US9803202B2 (en) 2017-10-31
JP2015521626A (ja) 2015-07-30
HK1244509A1 (zh) 2018-08-10
CA2876180A1 (en) 2013-12-27
US20130344135A1 (en) 2013-12-26
JP6208228B2 (ja) 2017-10-04
WO2013192576A3 (en) 2014-04-03
US10337005B2 (en) 2019-07-02
KR101928418B1 (ko) 2018-12-12
EP2864482A4 (en) 2016-02-10
CN107236735A (zh) 2017-10-10
EP3354734A1 (en) 2018-08-01
CN107236735B (zh) 2019-11-08
HK1209781A1 (en) 2016-04-08
AU2013278011B2 (en) 2018-09-20
MX2014015643A (es) 2015-07-17
US20160326526A1 (en) 2016-11-10
EP3354734B1 (en) 2020-06-10
ES2801875T3 (es) 2021-01-14
DK3354734T3 (da) 2020-06-29
EP2864482A2 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
MX355408B (es) Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
MX2021015290A (es) Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
MX2013005875A (es) Inhibidores de microarn que comprenden nucleotidos bloqueados.
NZ797319A (en) Modified rnai agents
MD20150006A2 (ro) Inhibitori de micro-ARN din familia miR-15
MX2013009191A (es) Oligonucleotidos antisentido.
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
WO2014154835A3 (en) Modified tgf-beta oligonucleotides
EA200870402A1 (ru) Фармацевтическая композиция
EA201100813A1 (ru) Фармацевтическая композиция
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
NZ592867A (en) Compositions and methods for inhibiting expression of transthyretin
MX2011013176A (es) Motivos de modificación química para inhibidores y miméticos del miarn.
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
MX2010004452A (es) Acido ribonucleico de doble cadena modificado con lipidos que tienen un potente efecto de interferencia de acido ribonucleico.
WO2011153323A8 (en) Compositions and methods directed to treating liver fibrosis
WO2012142313A3 (en) Micro-rna inhibitors and their uses in disease
WO2012177949A3 (en) Compositions and methods for inhibition of expression of protein c (proc) genes
WO2010003420A3 (en) Treatment of psoriasis and related diseases by mirna modulation
IN2014CN03921A (es)
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
AR079649A1 (es) Composiciones y metodos para inhibir la expresion de genes il-18
JP2018520150A5 (es)

Legal Events

Date Code Title Description
FG Grant or registration